Affordable Access

Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma

Authors
  • Hassan, Wael Abdo1, 2
  • Ibrahim, Rehab1, 3
  • 1 Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
  • 2 Department of Basic Sciences, Sulaiman Al Rajhi University, Al-Bukayriyah, KSA
  • 3 Department of Pathology, Collage of Medicine, Jouf University, Sakaka, KSA
Type
Published Article
Journal
International journal of clinical and experimental pathology
Publication Date
Aug 01, 2020
Volume
13
Issue
8
Pages
2115–2122
Identifiers
PMID: 32922608
PMCID: PMC7476947
Source
PubMed Central
Keywords
License
Unknown

Abstract

Background: The risk of endometrial hyperplasia progressing into endometrioid carcinoma ranges from 1% for benign hyperplasia to 46.2% for endometrial intra-epithelial neoplasia. Differentiation between both types of hyperplasia is thus crucial for optimal management. The present study investigates the expression of the following immune-histochemical markers, for their potential roles in differentiating between both types of endometrial hyperplasia; as well as their expression in endometrial carcinoma: VEGF, CD34 and CD117. Methods: Tissue samples were obtained, fixed, processed, stained by hematoxylin and eosin for diagnosis, and then imunohistochemically stained using anti CD117, CD34, and VEGF antibodies. Results: In benign endometrial hyperplasia, the cells show weak expression to VEGF and CD34, and absent CD117. In endometrial intra-epithelial neoplasia, the cells show strong expression of VEGF and weak expression of CD34 and CD117. In case of endometrioid carcinoma, all cases showed strong reaction for VEGF and CD34, and moderate expression to CD117. Conclusion: Our data suggests a role for CD117, CD34, and VEGF in progression from hyperplasia to carcinoma.

Report this publication

Statistics

Seen <100 times